Exenterations 60 Years after first description; Results of a survey among US and German gynecologic oncology centers

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 974-977

  Marnitz, Simone ^a   Dowdy, Sean ^b   Lanowska, Malgorzata ^a   Schneider, Achim ^a   Podratz, Karl ^b   Köhler, Christhardt ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Chemoradiation; Indication; Palliative exenteration; Pelvic exenteration; Primary cervical cancer; Recurrent cervical cancer; Survey

Indexed keywords

ADJUVANT THERAPY; ARTICLE; BLADDER FISTULA; CANCER CENTER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; GERMANY; HEALTH SURVEY; IMAGING; LYMPH NODE; MEDICAL EDUCATION; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGANIZATION; OUTPATIENT DEPARTMENT; PALLIATIVE THERAPY; PATIENT CARE; PELVIS SURGERY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; QUESTIONNAIRE; RECTUM FISTULA; SURGEON; TEACHING HOSPITAL; TRAINING; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNITED STATES; UTERINE CERVIX CANCER; CLINICAL TRIAL; FEMALE; HUMAN; MORTALITY; MULTICENTER STUDY; PELVIS EXENTERATION; POSTOPERATIVE COMPLICATION; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

FEMALE; GERMANY; HUMANS; PELVIC EXENTERATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUESTIONNAIRES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 69349107489     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a8351e     Document Type: Article

References (39)

1. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. Cancer. 1948;1:177-183.
2. Höckel M, Dornhö fer K. Pelvic exenterations for gynecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7:837-847.
3. Marnitz S, Köhler C, Müller M, et al. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol. 2006;103:1023-1030.
4. Berek JS, Howe C, Lagasse LD, et al. Pelvic exenteration for recurrent gynaecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005;99:153-159.
5. Estape R, Angioli R. Surgical management of advanced and recurrent cervical cancer. Semin Surg Oncol. 1999;16:236-241.
6. Goldberg JM, Piver S, Hempling RE, et al. Improvement in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol. 1998;5:399-406.
7. Lambrou NC, Pearson JM, Averette HE. Pelvic exenteration of gynecologic malignancy: indications, and technical and reconstructive considerations. Surg Oncol Clin N Am. 2005; 14:289-300.
8. Magrina JF, Stanhope CR, Waever AL. Pelvic exenterations: supralevator, infralevator, and with vulvectomy. Gynecol Oncol. 1997;64:130-135.
9. Matthews CM, Morris M, Burke TW, et al. Pelvic exenteration in the elderly patient. Obstet Gynecol. 1992;79:773-777.
10. Morley GW, Hopkins MP, Lindenauer SM, et al. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. 1989;74:934-943.
11. Rutledge FN, Smith JP, Wharton JT, et al. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol. 1977;129:881-892.
12. Sharma S, Odunsi K, Driscoll D, et al. Pelvic exenteration for gynecological malignancies: twenty-year experience at Rosewell Park Cancer Institute. Int J Gynecol Cancer. 2005;15:475-482.
13. Shingelton HM, Soong SJ, Gelder MS, et al. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol. 1989;73:1027-1034.
14. Soper JT, Berchuck A, Creasman WT, et al. Pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol. 1989;35:93-98.
15. Stanhope CR, Symmonds RE. Palliative exenteration-what, when, and why? Am J Obstet Gynecol. 1985;152:12-16.
16. Symmonds RE, Pratt JH, Webb MJ. Exenterative operations: experience with 198 patients. Am J Obstet Gynecol. 1975; 121:907-918.
17. Crowe PJ, Temple WJ, Lopez MJ, et al. Pelvic exenteration for advanced pelvic malignancy. Semin Surg Oncol. 1999;17:152-160.
18. Hawighorst-Knapstein S, Fusshoeller C, Franz C, et al. The impact of treatment for genital cancer on quality of live and body image-results of a prospective longitudinal 10-year study. Gynecol Oncol. 2004; 94:398-403.
19. Roos EJ, de Graeff A, van Eijkeren MA, et al. Quality of live after pelvic exenteration. Gynecol Oncol. 2004;93:610-614.
20. Saunders N. Pelvic exenteration: by whom and for whom? Lancet. 1995;345:5-6.
21. Bricker EM. Bladder substitution after pelvic evisceration. Surg Clin North Am. 1950;30:1511-1521.
22. Houvenaeghel G, Moutardier V, Karsenty G, et al. Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol Oncol. 2004;92:680-683.
23. Ungar L, Palfalvi L. Pelvic exenteration without external urinary or fecal diversion in gynecological cancer patients. Int J Gynecol Cancer. 2006;16:364-368.
24. Ketcham AS, Deckers PJ, Sugarbaker EV, et al. Pelvic exenteration for carcinoma of the uterine cervix-a 15-year experience. Cancer. 1970; 26:513-521.
25. Roberts WS, Cavanagh D, Bryson P, et al. Major morbidity after pelvic exenteration. A seven-year experience. Obstet Gynecol. 1987;69:617-621.
26. Kramer C, Peschel RE, Goldberg N, et al. Radiation treatment of FIGO stage IVA carcinoma of the cervix. Gynecol Oncol. 1989; 32: 323-326.
27. Moore KN, Gold MA, McMeekin DS, et al. Vesicovaginal fistula formation in patients with stage IVA cervical cancer. Gynecol Oncol. 2007;106:498-501.
28. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143.
29. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002;20:966-972.
30. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecology Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
31. IngiullaW, Cosmi EV. Pelvic exenteration for advanced carcinoma of the cervix. Am J Obstet Gynecol. 1967;99:1083-1086.
32. Hertel H, Köhler C, Elhawary T, et al. Laparoscopic staging compared with imaging techniques in the staging of advanced cervical cancer. Gynecol Oncol. 2002;87:46-51.
33. Husain A, Akhurst T, Larson T, et al. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18 FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol. 2007; 106:177-180.
34. Köhler C, Tozzi R, Possover M, et al. Explorative laparoscopy prior to exenterative surgery. Gynecol Oncol. 2002;86:311-315.
35. Martinez-Monge R, Jurado M, Cambeiro M, et al. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecologic cancer: initial results of a phase II trial. Brachytherapy. 2006;5:203-210.
36. Long HJ, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:4626-4633.
37. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119.
38. Kasamatsu T, Onda T, Yamada T, et al. Clinical aspects and prognosis of pelvic recurrence of cervical carcinoma. Int J Gynecol Obstet. 2005;89:39-44.
39. Benedetti Panici P, Bellati F, Manci N, et al. Neoadjuvant chemotherapy followed by radical surgery in patients affected by FIGO stage IVA cervical cancer. Ann Surg Oncol. 2007;14:2643-2648.